

Presentation

Charlotte Stange
Global Head of Sustainability

June 13, 2024

Sustainability Expert Call

Safe harbor statement: In this Safe harbor statement, “the Company” and “Fresenius Medical Care” refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conversion of legal form. This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in the Company’s Annual Report on Form 20-F under the headings “Forward-Looking Statements” and “Risk Factors” and under the headings in that report referred to therein, and in the Company’s other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care. Amounts are in Euro if not mentioned otherwise.

Implementation of measures as presented herein may be subject to information and consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.

OUR VISION

**CREATING A FUTURE WORTH LIVING.
FOR PATIENTS.
WORLDWIDE.
EVERY DAY.**

Our commitment to sustainability | Purpose driven. Patient-centric.

Progress in our strategic focus areas



Enhance quality of care and access to health care

High patient satisfaction
72
Net Promoter Score

Scientific progress
>170
research documents published

Build the best team to serve patients

Diversity in leadership
34%
women in the first two levels below the Management Board

Employee development
>38
training hours per employee

Reduce our environmental footprint

Emissions reduction
16%
less CO₂e emissions compared to baseline year 2020¹


Environmental initiatives
100
projects at production sites

¹ Includes Scope 1 (direct) and Scope 2 (indirect) emissions at our production sites and Scope 2 emissions from electricity consumption resulting from treatments at our dialysis clinics | excluding mobile assets | market-based emissions
Data as of FY 2023

Focus today | Reducing our environmental footprint

Progress with our climate action plan

Reducing our Scope 1 and 2 emissions¹



Global climate targets

- 2030** 50% reduction of CO₂e Scope 1 and 2 emissions compared with 2020
- 2040** Climate neutral in own operations

Progress achieved

- Renewable electricity** purchasing and production
- Energy efficiency** measures in our operations at production sites and clinics

¹ Includes Scope 1 (direct) and Scope 2 (indirect) emissions at our production sites and Scope 2 emissions from electricity consumption resulting from treatments at our dialysis clinics | excluding mobile assets | market-based emissions
Data as of FY 2023

Our climate action journey

2014 to 2021

- Built eco-friendly clinic in Terrassa
- Started energy management systems installation to cover 1,400+ U.S. clinics by 2024
- Launched Green & Lean Initiative for production sites with ~500 environmental projects since 2020
- Implemented Global Environmental Expert Network

2022

Set global goals

- 50% reduction of Scope 1 and 2 emissions by 2030
- Climate neutral by 2040

2023

- 16% Scope 1 and 2 emissions reduction against base year 2020
- Energy efficiency workshops for all major production sites
- Global value chain greenhouse gas emissions (Scope 3) assessment

2024

- Signed five virtual power purchase agreements for solar and wind farms in the U.S. and Europe
- Commitment letter submitted to science-based targets initiative (SBTi)
- 100+ opportunities identified in energy efficiency assessments for production sites
- Emission reduction included in Management Board compensation

Progress in renewable electricity procurement achieved



Virtual power purchase agreements signed

- Signed five virtual power purchase agreements with solar and wind farms in Germany and the U.S.
- Long term, large scale renewable electricity procurement contracts that feed additional renewable electricity into the grid
- Sites are predicted to produce enough electricity to cover 46% of FME's current consumption once operational

Case study | Production sites

Prioritize energy efficiency in manufacturing processes

Ambition

- Optimize utility control setpoints to increase energy efficiency

Impact

- Various measures implemented, e.g., adjust temperature of purified water loop and chillers, recover heat from steam condensate, install automated control systems
- Expected energy savings: 130,000+ MWh



Case study | Clinic network

Drive energy efficiency across our clinics network



Ambition

- Install energy management systems at U.S. clinics to increase energy efficiency

Impact

- Allows remote monitoring and regulating temperature settings in the clinic
- Around 1,400 locations across the U.S. to be covered by end of 2024
- Energy savings: ~15 MWh on average in each clinic

Case study | Clinic network

Increase renewable energy production for clinics

Ambition

- Increase renewable energy production countrywide, install solar panels to half of Portuguese clinics by end of 2024

Impact

- Covers up to 30% of energy need of individual clinics

Planned for 2024


- 10 sites in northern Portugal

Installed by end 2023

- 10 sites in southern Portugal

Emissions in the value chain

Overview | Scope 1, 2, and 3 emissions



- Global value chain greenhouse gas emissions (Scope 3) assessment disclosed in Non-Financial Report 2023
- Commitment letter submitted to Science Based Targets initiative (SBTi)
- Development of Scope 3 targets in line with SBTi commitment ongoing



Your questions are welcome.

Contacts

Fresenius Medical Care AG

Investor Relations
Else-Kröner-Str. 1
61352 Bad Homburg v. d. H.
Germany

✉ ir@freseniusmedicalcare.com

Ticker:
FME or FMS (NYSE/ADR)

WKN:
578 580

ISIN:
DE00057858002

CUSIP (ADR):
358029106

Dr. Dominik Heger

Head of Investor Relations
and
Head of Investor Relations,
Strategic Development &
Communications | EVP

+49(0) 6172-609-2525

dominik.heger@freseniusmedicalcare.com

Ilia Kuerten

Vice President
Investor Relations

+49(0) 6172-268-5966

ilia.kuerten@freseniusmedicalcare.com

Alicia Cahill

Senior Director
Investor Relations

+1 860-609-2394

alicia.cahill@freseniusmedicalcare.com